https://www.investing.com/news/press-releases/lowey-dannenberg-pc-is-investigating-inari-medical-inc-inari-or-the-company-nasdaqnari-for-potential-violations-of-the-federal-securities-laws-and-encourages-investors-with-more-t-93CH-3386956
IRVINE, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its first quarter 2024 financial results on Tuesday, April 30, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
Inari Medical, Inc. (NARI) releases its 2023 Ethos and Sustainability Report, showcasing its commitment to ESG initiatives. The report emphasizes the company''s dedication to treating patients with venous and other diseases while prioritizing environmental and social responsibilities.
IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the publication of its 2023 Ethos and Sustainability Report. The report highlights Inari’s commitment to its ethos and important corresponding environmental, social and governance (ESG) initiatives. The report can be found on Inari’s website here.
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Inari Medical Inc. (“Inari” or the “Company”) (NASDAQ:NARI) for potential violations of the federal securities laws. The firm’s investigation is in connection with Inari’s recent disclosure that the U.S. Department of Justice sent the Company a civil investigative demand concerning an investigation under the federal Anti-Kickback Statute and Civil False Claims Act, related to payments made to healthcare professionals.
https://www.investing.com/news/company-news/inari-medical-hires-new-sales-and-medical-affairs-vps-93CH-3362685
NEW YORK, NY - ( NewMediaWire ) - March 19, 2024 - Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of Inari Medical, Inc. (“Inari Medical” or the “Company”) (NASDAQ: NARI). Click here to join the investigation. If you acquired Inari Medical shares and would like to discuss our investigation, please click here or contact us by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. On February 28, 2024, after the market close, Inari Medical announced fourth quarter and full-year 2023 financial results and disclosed receipt of a civil investigative demand in December 2023 from the U.S. Department of Justice (“DOJ”) “requesting information primarily related to meals and consulting service payments provided to healthcare professionals.” In the Company’s Annual Report filed the next day with the SEC, Inari Medical indicated that that the DOJ request was in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act.
NEW YORK, NY - ( NewMediaWire ) - March 18, 2024 - Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of Inari Medical, Inc. (“Inari Medical” or the “Company”) (NASDAQ: NARI). Click here to join the investigation. If you acquired Inari Medical shares and would like to discuss our investigation, please click here or contact us by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. On February 28, 2024, after the market close, Inari Medical announced fourth quarter and full-year 2023 financial results and disclosed receipt of a civil investigative demand in December 2023 from the U.S. Department of Justice (“DOJ”) “requesting information primarily related to meals and consulting service payments provided to healthcare professionals.” In the Company’s Annual Report filed the next day with the SEC, Inari Medical indicated that that the DOJ request was in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act.